DURECT Corporation (DRRX)
Market Cap | 42.21M |
Revenue (ttm) | 8.32M |
Net Income (ttm) | -23.28M |
Shares Out | 31.04M |
EPS (ttm) | -0.98 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 99,300 |
Open | 1.340 |
Previous Close | 1.310 |
Day's Range | 1.300 - 1.450 |
52-Week Range | 0.470 - 5.280 |
Beta | 1.12 |
Analysts | Buy |
Price Target | 23.00 (+1,591.18%) |
Earnings Date | Aug 7, 2024 |
About DRRX
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osm... [Read more]
Full Company ProfileFinancial Performance
In 2023, DURECT's revenue was $8.55 million, a decrease of -55.67% compared to the previous year's $19.28 million. Losses were -$27.62 million, -21.82% less than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for DRRX stock is "Buy." The 12-month stock price forecast is $23.0, which is an increase of 1,591.18% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/f/k/press11-2441249.jpg)
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial CUPERTINO, Calif. , May 21, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-...
![](https://cdn.snapi.dev/images/v1/a/a/press7-2428028.jpg)
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update
- FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Earnings Call Today, May 13th at 4:30 p.m. ET CUPERTINO, Calif.
![](https://cdn.snapi.dev/images/v1/b/n/conf13-2416381.jpg)
DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update
CUPERTINO, Calif. , May 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment ...
![](https://cdn.snapi.dev/images/v1/q/7/press20-2399249.jpg)
DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis
CUPERTINO, Calif. , April 30, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatme...
![](https://cdn.snapi.dev/images/v1/w/u/press2-2344872.jpg)
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Ongoing Communication with FDA to Align on Next Steps for Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Earnings Call Today, March 27th at 4:30 p.m. ET CUPERTINO, Calif.
![](https://cdn.snapi.dev/images/v1/o/w/conf18-2334125.jpg)
DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
CUPERTINO, Calif. , March 20, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatme...
![](https://cdn.snapi.dev/images/v1/w/n/press4-2305881.jpg)
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada
Partnership agreement will be the first-ever co-marketing and sales collaboration for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada Both companies will jointly m...
![](https://cdn.snapi.dev/images/v1/e/q/conf11-2265994.jpg)
DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
CUPERTINO, Calif. , Feb. 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E.
![](https://cdn.snapi.dev/images/v1/x/x/image22-2199829.jpeg)
Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
![](https://cdn.snapi.dev/images/v1/x/n/press12-2155586.jpg)
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update
- Webcast of Earnings Call Today, November 13th at 4:30 p.m. ET - Topline data from AHFIRM trial showed compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortalit...
![](https://cdn.snapi.dev/images/v1/p/1/conf5-2151222.jpg)
DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update
CUPERTINO, Calif. , Nov. 9, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment...
![](https://cdn.snapi.dev/images/v1/f/d/press5-2145195.jpg)
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality
Compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days. Clinically relevant reduction in 90-day mortality of 41% for 30 mg dose and 35% for 90 mg d...
![](https://cdn.snapi.dev/images/v1/m/0/press7-2053177.jpg)
DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis
Company on track to report topline data from AHFIRM in Q4 2023 CUPERTINO, Calif. , Sept. 7, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering th...
![](https://cdn.snapi.dev/images/v1/7/s/conf17-2045902.jpg)
DURECT Corporation Announces Presentations in Upcoming Investor Conferences
CUPERTINO, Calif. , Aug. 31, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver disease...
![](https://cdn.snapi.dev/images/v1/r/x/press9-2015728.jpg)
DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update
- Webcast of Earnings Call Today, August 9th at 4:30 p.m. ET - Topline data from AHFIRM trial expected in Q4 2023 CUPERTINO, Calif.
![](https://cdn.snapi.dev/images/v1/j/u/conf19-2005953.jpg)
DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update
CUPERTINO, Calif. , Aug. 3, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases...
![](https://cdn.snapi.dev/images/v1/x/w/press17-1980017.jpg)
DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
CUPERTINO, Calif. , July 20, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of ...
![](https://cdn.snapi.dev/images/v1/q/q/press20-1924152.jpg)
DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis
Topline data anticipated in Q4 2023 CUPERTINO, Calif. , June 7, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company developing epigenetic therapies for the treatment of...
![](https://cdn.snapi.dev/images/v1/v/k/press15-1877919.jpg)
DURECT Corporation Reports First Quarter 2023 Financial Results and Business Update
- Webcast of Earnings Call Today, May 8th at 4:30 p.m. ET - Topline data from AHFIRM trial expected in 2H 2023 CUPERTINO, Calif.
![](https://cdn.snapi.dev/images/v1/c/b/conf8-1864433.jpg)
DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8
CUPERTINO, Calif. , May 1, 2023 /PRNewswire/ --- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2023 financial results and host a conference call after the mar...
![](https://cdn.snapi.dev/images/v1/n/c/press19-1859609.jpg)
DURECT Corporation to Host KOL Event on Alcohol-Associated Hepatitis
CUPERTINO, Calif., April 27, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will host a Key Opinion Leader ("KOL") event on Alcohol-Associated Hepatitis on May 16th in New Y...
![](https://cdn.snapi.dev/images/v1/l/9/conf17-1853800.jpg)
DURECT Corporation to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference
CUPERTINO, Calif. , April 25, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO, will participate in a fireside chat hosted by Ed Arce, Man...
![](https://cdn.snapi.dev/images/v1/p/r/press7-1830345.jpg)
DURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated Hepatitis
Data expands upon previously reported results, including individual patient data, additional liver biomarkers, and comparisons to matching arms from a contemporaneous study
![](https://cdn.snapi.dev/images/v1/s/u/press9-1806886.jpg)
DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board
CUPERTINO, Calif. , March 21, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023.
![](https://cdn.snapi.dev/images/v1/7/a/press2-1789359.jpg)
DURECT Corporation Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference
CUPERTINO, Calif. , March 9, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO and additional members of the management team will participa...